MTOR and breast carcinoma: Preliminary efficacy data from the phase 1 single-agent studies indicate antitumour activities (in addition to breast cancer and renal cell carcinoma) of mTOR inhibitors (CCI-779, RAD001 and AP23573) in patients with non-small-cell lung cancer, anaplastic astrocytoma, mesothelioma, soft tissue sarcoma, cervical and uterine cancer (O'Donnell et al, 2003; Mita et al, 2004).